Account

New to ADSS? Open an
account now to get started.

OR

Already have an account?

Add funds to your ADSS account

Account

New to ADSS? Open an
account now to get started.

Add funds to your ADSS account

Trends & Analysis
News

Week Ahead Preview: 17th of February

News

Europe stocks hit record high on strong earnings

News

BRIC currencies mostly gain as US inflation rises

News

Refresh your portfolio with Coca-Cola?

News

GBP/USD price may rally to multi-week high

News

EIA ups oil output forecast, but supply fears loom

Trends & Analysis
News

Week Ahead Preview: 17th of February

News

Europe stocks hit record high on strong earnings

News

BRIC currencies mostly gain as US inflation rises

News

Refresh your portfolio with Coca-Cola?

News

GBP/USD price may rally to multi-week high

News

EIA ups oil output forecast, but supply fears loom

News

BioNTech shares spike on Q1 sales growth

 

Tuesday, May 10, 2022

The news shaping the markets today

The UN Human Rights Council announced plans to hold a special session on Thursday to address Russia’s alleged violations in the ongoing Ukraine war. The RUB/USD forex pair, meanwhile, traded higher this morning.


Japan’s household spending fell by 2.3% in March, following a 1.1% increase in February. This was the first downturn in personal spending since last December and exerting pressure on the JPY/USD pair in forex trading this morning.


Australia’s NAB business confidence index fell to 10 in April, from a 5-month high of 16 a month ago. The news sent the AUD/USD forex pair sharply lower.


UK’s retail sales contracted by 1.7% year-over-year in April, following a 0.4% decline in the prior month. However, the GBP/USD pair rose in forex trading this morning.


New Zealand’s electronic card transactions climbed 7% in April, after declining for two straight months. Despite this being the strongest monthly growth in card spending since last November, the NZD/USD forex pair remained under pressure.

 

What’s happening: Shares of BioNTech SE gained on Monday, after the company reported a sharp rise in sales and earnings for its first quarter.

What happened: The German biotech firm reiterated its forecast for covid-19 vaccine sales for the full year.

However, one of the company’s major rivals issued a more bullish sales forecast for their covid-19 vaccine last week.

How were the results: The Mainz, Germany-based company reported a surge in sales and earnings for the first quarter, with both figures exceeding market views.

 

  • Sales grew a whopping 211% year-over-year to €6.37 billion, beating the consensus estimate of $4.59 billion.
  • Net profits more than doubled to €3.69 billion.
  • Adjusted earnings jumped 224% to €14.24 per share, easily surpassing market expectations.

Why it matters: Demand for covid-19 vaccines has been easing in regions like North America and Europe, with most people willing to take the shot having already received their booster doses. Further doses are now being recommended only for vulnerable senior citizens.

BioNTech and its vaccine partner Pfizer sold around 750 million covid-19 vaccine doses during the first quarter. As of end-April 2022, orders for around 2.4 billion vaccine doses have been signed by the companies to be delivered through the year. With this, the companies are on course to delivering over 2 billion vaccine doses to low- and middle-income countries by the end of 2022.

BioNTech recorded an operating income of €4.75billion for the quarter, up from €1.67 billion in the year-earlier period.

BioNTech reiterated its forecast of between €13 billion and €17 billion in covid-19 vaccine sales in 2022, which translates to between $13.74 billion and $17.96 billion in revenues. This is lower than the sales of €19 billion recorded in 2021.

Meanwhile, rival covid-19 vaccine maker Moderna issued a more bullish forecast, projecting higher covid-19 vaccine sales during the second half of the year citing demand for booster doses during autumn.

How shares responded: BioNTech’s American Depositary Receipts gained 3.1% to settle at $140.32 on Monday, following the release of quarterly results. The stock has lost more than 39% since the start of the year.

What to watch: Investors will keep an eye on the spread of covid-19 infections, as a resurgence could provide another boost to the company’s vaccine sales. Markets also await trial data from BioNTech’s shot developed specifically for the Omicron variant.

The markets today

Crude oil will be in focus today, ahead of the API’s (American Petroleum Institute) data on crude oil stockpiles

 

Context: Oil futures fell sharply on Monday, amid growing concerns around the Chinese economy.

Details: Investors are concerned about interest rate hikes in China and the possibility of the economy heading for a recession due to tighter covid-19 restrictions.

US stocks fell sharply, with the greenback surging to a two-decade high on Monday, making crude more expensive for foreign currency holders.

China also released disappointing trade data on Monday, which fuelled concerns around energy demand from the second-largest consumer of oil. Although exports from China grew by 3.9% year-over-year to $273.62 billion in April, the rate moderated sharply from 14.7% in the previous month. China’s imports also stalled from a year ago at $222.50 billion in April.

During the first four months of the year, crude imports by China declined 4.8% year-over-year.

Last week, European Commission President Ursula von der Leyen announced a proposal for a gradual embargo on Russian oil, which provided some support to oil prices. Meanwhile, Saudi Arabia reduced June prices for crude oil to Asia and Europe.

WTI crude for June delivery tumbled $6.68, or 6.1%, to close at $103.09 per barrel on the NYMEX on Monday. Brent crude for July delivery fell $6.45 to settle at $105.94 per barrel. Prices of both contracts have surged around 34% year to date.

In other energy trading, wholesale gasoline for June delivery declined 12 cents to $3.64 a gallon, while June natural gas slipped $1.01 to $7.03 per 1,000 cubic feet on Monday.

What to watch: Traders await the release of API’s data on US crude oil stockpiles, which had contracted by 3.479 million barrels in the week ending April 29, following a 4.78 million barrel increase in the prior week.

Markets will also keep an eye on the ongoing war in Ukraine and rising covid-19 cases in some parts of the world.

Other Markets: European trading indices closed lower on Monday, with the FTSE 100, DAX 40, CAC 40 and STOXX Europe 600 down by 2.32%, 2.15%, 2.75% and 2.90%, respectively.

Support & resistances for today

Technical Levels News Sentiment
EUR/USD – 1.0557 and 1.0571 Positive
USD/JPY – 129.82 and 130.12 Negative
WTI Crude Oil – 100.37 and 101.91 Positive
Natural Gas – 7.042 and 7.084 Positive
Nikkei 225 – 25793.84 and 25882.34 Positive

Market snapshot

What else to watch today

Saudi Arabia’s industrial production, Turkey’s unemployment rate and labour force participation rate, Italy’s industrial production, Eurozone’s ZEW indicator of economic sentiment, Germany’s ZEW indicator of economic sentiment and ZEW current conditions, US NFIB small business optimism index, Redbook index and IBD/TIPP economic optimism index, Brazil’s retail sales, car production, auto sales, current account, foreign direct investment, value of loans and Central Bank of Brazil’s Copom meeting minutes, South Africa’s SACCI business confidence index, as well as India’s central government budget value.


Site by Pink Green
© ADSS 2025


Investing in CFDs involves a high degree of risk that you will lose your money due to the use of leverage, particularly in fast moving markets, where a relatively small movement in the price can lead to a proportionately larger movement in the value of your investment. This can result in loses that exceed the funds in your account. You should consider whether you understand how CFDs work and you should seek independent advice if necessary.

ADS Securities LLC – S.P.C (“ADSS”) is authorised and regulated by the Securities and Commodities Authority (“SCA”) in the United Arab Emirates under First Category: Dealing in Securities and Fifth category: Arrangement and advice (Introduction). ADSS is a Limited Liability Company – Sole Proprietorship Company incorporated under United Arab Emirates law. The company is registered with the Department of Economic Development of Abu Dhabi (No. 1190047) and has its principal place of business at 8th Floor, CI Tower, Corniche Road, P.O. Box 93894, Abu Dhabi, United Arab Emirates.

The information presented is not directed at residents of any particular country outside the United Arab Emirates and is not intended for distribution to, or use by, any person in any country where the distribution or use is contrary to local law or regulation.

ADSS is an execution only service provider and does not provide advice. ADSS may publish general market commentary from time to time. Where it does, the material published does not constitute advice, or a solicitation, or a recommendation to a transaction in any financial instrument. ADSS accepts no responsibility for any use of the content presented and any consequences of that use. No representation or warranty is given as to the completeness of this information. Anyone acting on the information provided does so at their own risk.